Which has preferable valuation & earnings, CPH or CRON?

Cipher Pharmaceuticals has higher earnings, but lower revenue than Cronos Group. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cipher Pharmaceuticals C$50.94M 8.33 C$11.41M C$1.19 14.04 Cronos Group C$159.54M 8.83 -C$32.78M N/A N/A

Do analysts prefer CPH or THCX?

Cipher Pharmaceuticals presently has a consensus price target of C$17.00, indicating a potential upside of 1.74%. Given Cipher Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts clearly believe Cipher Pharmaceuticals is more favorable than Hydropothecary. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cipher Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Hydropothecary 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has preferable valuation & earnings, CPH or THCX?

Cipher Pharmaceuticals has higher revenue and earnings than Hydropothecary. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cipher Pharmaceuticals C$50.94M 8.33 C$11.41M C$1.19 14.04 Hydropothecary N/A N/A N/A N/A N/A

Cipher Pharmaceuticals (CPH) Competitors

C$16.71 -0.13 (-0.77%)

As of 06/2/2026 04:00 PM Eastern

Compare

CPH vs. CRON, THCX, TLRY, DHT.UN, and GUD

Should you buy Cipher Pharmaceuticals stock or one of its competitors? MarketBeat compares Cipher Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Cipher Pharmaceuticals include Cronos Group (CRON), Hydropothecary (THCX), Tilray Brands (TLRY), DRI Healthcare Trust (DHT.UN), and Knight Therapeutics (GUD). These companies are all part of the "drug manufacturers - specialty & generic" industry.

How does Cipher Pharmaceuticals compare to Cronos Group?

Cipher Pharmaceuticals (TSE:CPH) and Cronos Group (TSE:CRON) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, risk, institutional ownership, media sentiment, earnings, valuation, dividends and analyst recommendations.

Cipher Pharmaceuticals has higher earnings, but lower revenue than Cronos Group.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cipher Pharmaceuticals	C$50.94M	8.33	C$11.41M	C$1.19	14.04
Cronos Group	C$159.54M	8.83	-C$32.78M	N/A	N/A

Cipher Pharmaceuticals has a net margin of 60.82% compared to Cronos Group's net margin of -1.29%. Cipher Pharmaceuticals' return on equity of 25.69% beat Cronos Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cipher Pharmaceuticals	60.82%	25.69%	7.90%
Cronos Group	-1.29%	-0.19%	-3.73%

In the previous week, Cipher Pharmaceuticals' average media sentiment score of 0.00 equaled Cronos Group'saverage media sentiment score.

Company	Overall Sentiment
Cipher Pharmaceuticals	Neutral
Cronos Group	Neutral

Cipher Pharmaceuticals has a beta of 0.894897, suggesting that its share price is 11% less volatile than the broader market. Comparatively, Cronos Group has a beta of 1.11805, suggesting that its share price is 12% more volatile than the broader market.

Cipher Pharmaceuticals currently has a consensus price target of C$17.00, suggesting a potential upside of 1.74%. Cronos Group has a consensus price target of C$4.75, suggesting a potential upside of 25.99%. Given Cronos Group's stronger consensus rating and higher probable upside, analysts plainly believe Cronos Group is more favorable than Cipher Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cipher Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Cronos Group	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00

2.3% of Cipher Pharmaceuticals shares are held by institutional investors. Comparatively, 4.4% of Cronos Group shares are held by institutional investors. 42.0% of Cipher Pharmaceuticals shares are held by company insiders. Comparatively, 46.4% of Cronos Group shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Cronos Group beats Cipher Pharmaceuticals on 8 of the 13 factors compared between the two stocks.

How does Cipher Pharmaceuticals compare to Hydropothecary?

Cipher Pharmaceuticals (TSE:CPH) and Hydropothecary (CVE:THCX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, media sentiment, profitability, analyst recommendations, risk, valuation and dividends.

Cipher Pharmaceuticals has a net margin of 60.82% compared to Hydropothecary's net margin of 0.00%. Cipher Pharmaceuticals' return on equity of 25.69% beat Hydropothecary's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cipher Pharmaceuticals	60.82%	25.69%	7.90%
Hydropothecary	N/A	N/A	N/A

Cipher Pharmaceuticals presently has a consensus price target of C$17.00, indicating a potential upside of 1.74%. Given Cipher Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts clearly believe Cipher Pharmaceuticals is more favorable than Hydropothecary.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cipher Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Hydropothecary	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

2.3% of Cipher Pharmaceuticals shares are owned by institutional investors. 42.0% of Cipher Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Cipher Pharmaceuticals has higher revenue and earnings than Hydropothecary.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cipher Pharmaceuticals	C$50.94M	8.33	C$11.41M	C$1.19	14.04
Hydropothecary	N/A	N/A	N/A	N/A	N/A

In the previous week, Cipher Pharmaceuticals' average media sentiment score of 0.00 equaled Hydropothecary'saverage media sentiment score.

Company	Overall Sentiment
Cipher Pharmaceuticals	Neutral
Hydropothecary	Neutral

Summary

Cipher Pharmaceuticals beats Hydropothecary on 8 of the 8 factors compared between the two stocks.

How does Cipher Pharmaceuticals compare to Tilray Brands?

Cipher Pharmaceuticals (TSE:CPH) and Tilray Brands (TSE:TLRY) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, earnings, institutional ownership, valuation, dividends, profitability and media sentiment.

Cipher Pharmaceuticals has higher earnings, but lower revenue than Tilray Brands. Tilray Brands is trading at a lower price-to-earnings ratio than Cipher Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cipher Pharmaceuticals	C$50.94M	8.33	C$11.41M	C$1.19	14.04
Tilray Brands	C$858.28M	1.04	-C$183.24M	-C$14.63	N/A

In the previous week, Tilray Brands had 3 more articles in the media than Cipher Pharmaceuticals. MarketBeat recorded 3 mentions for Tilray Brands and 0 mentions for Cipher Pharmaceuticals. Tilray Brands' average media sentiment score of 0.42 beat Cipher Pharmaceuticals' score of 0.00 indicating that Tilray Brands is being referred to more favorably in the news media.

Company	Overall Sentiment
Cipher Pharmaceuticals	Neutral
Tilray Brands	Neutral

Cipher Pharmaceuticals has a beta of 0.894897, meaning that its share price is 11% less volatile than the broader market. Comparatively, Tilray Brands has a beta of 3.243166, meaning that its share price is 224% more volatile than the broader market.

Cipher Pharmaceuticals currently has a consensus target price of C$17.00, suggesting a potential upside of 1.74%. Tilray Brands has a consensus target price of C$13.30, suggesting a potential upside of 78.76%. Given Tilray Brands' higher probable upside, analysts plainly believe Tilray Brands is more favorable than Cipher Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cipher Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Tilray Brands	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

2.3% of Cipher Pharmaceuticals shares are held by institutional investors. Comparatively, 4.1% of Tilray Brands shares are held by institutional investors. 42.0% of Cipher Pharmaceuticals shares are held by company insiders. Comparatively, 0.7% of Tilray Brands shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Cipher Pharmaceuticals has a net margin of 60.82% compared to Tilray Brands' net margin of -158.75%. Cipher Pharmaceuticals' return on equity of 25.69% beat Tilray Brands' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cipher Pharmaceuticals	60.82%	25.69%	7.90%
Tilray Brands	-158.75%	-88.06%	-1.41%

Summary

Cipher Pharmaceuticals beats Tilray Brands on 8 of the 14 factors compared between the two stocks.

How does Cipher Pharmaceuticals compare to DRI Healthcare Trust?

Cipher Pharmaceuticals (TSE:CPH) and DRI Healthcare Trust (TSE:DHT.UN) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, risk, valuation, earnings, institutional ownership and dividends.

Cipher Pharmaceuticals presently has a consensus target price of C$17.00, indicating a potential upside of 1.74%. DRI Healthcare Trust has a consensus target price of C$25.50, indicating a potential upside of 37.84%. Given DRI Healthcare Trust's stronger consensus rating and higher possible upside, analysts plainly believe DRI Healthcare Trust is more favorable than Cipher Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cipher Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
DRI Healthcare Trust	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00

Cipher Pharmaceuticals has a beta of 0.894897, indicating that its share price is 11% less volatile than the broader market. Comparatively, DRI Healthcare Trust has a beta of 0.347429, indicating that its share price is 65% less volatile than the broader market.

Cipher Pharmaceuticals has higher earnings, but lower revenue than DRI Healthcare Trust. DRI Healthcare Trust is trading at a lower price-to-earnings ratio than Cipher Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cipher Pharmaceuticals	C$50.94M	8.33	C$11.41M	C$1.19	14.04
DRI Healthcare Trust	C$163.77M	6.21	C$9.73M	-C$0.90	N/A

Cipher Pharmaceuticals has a net margin of 60.82% compared to DRI Healthcare Trust's net margin of 5.02%. Cipher Pharmaceuticals' return on equity of 25.69% beat DRI Healthcare Trust's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cipher Pharmaceuticals	60.82%	25.69%	7.90%
DRI Healthcare Trust	5.02%	2.06%	4.22%

In the previous week, Cipher Pharmaceuticals' average media sentiment score of 0.00 equaled DRI Healthcare Trust'saverage media sentiment score.

Company	Overall Sentiment
Cipher Pharmaceuticals	Neutral
DRI Healthcare Trust	Neutral

2.3% of Cipher Pharmaceuticals shares are owned by institutional investors. Comparatively, 0.6% of DRI Healthcare Trust shares are owned by institutional investors. 42.0% of Cipher Pharmaceuticals shares are owned by company insiders. Comparatively, 0.1% of DRI Healthcare Trust shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Cipher Pharmaceuticals beats DRI Healthcare Trust on 10 of the 14 factors compared between the two stocks.

How does Cipher Pharmaceuticals compare to Knight Therapeutics?

Knight Therapeutics (TSE:GUD) and Cipher Pharmaceuticals (TSE:CPH) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, earnings, institutional ownership, media sentiment and dividends.

In the previous week, Knight Therapeutics' average media sentiment score of 0.00 equaled Cipher Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Knight Therapeutics	Neutral
Cipher Pharmaceuticals	Neutral

Cipher Pharmaceuticals has a net margin of 60.82% compared to Knight Therapeutics' net margin of 1.10%. Cipher Pharmaceuticals' return on equity of 25.69% beat Knight Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Knight Therapeutics	1.10%	0.73%	0.51%
Cipher Pharmaceuticals	60.82%	25.69%	7.90%

Knight Therapeutics has a beta of -0.214451, indicating that its share price is 121% less volatile than the broader market. Comparatively, Cipher Pharmaceuticals has a beta of 0.894897, indicating that its share price is 11% less volatile than the broader market.

Knight Therapeutics currently has a consensus target price of C$9.50, indicating a potential upside of 15.85%. Cipher Pharmaceuticals has a consensus target price of C$17.00, indicating a potential upside of 1.74%. Given Knight Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Knight Therapeutics is more favorable than Cipher Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Knight Therapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Cipher Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

23.2% of Knight Therapeutics shares are held by institutional investors. Comparatively, 2.3% of Cipher Pharmaceuticals shares are held by institutional investors. 45.6% of Knight Therapeutics shares are held by insiders. Comparatively, 42.0% of Cipher Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Cipher Pharmaceuticals has lower revenue, but higher earnings than Knight Therapeutics. Cipher Pharmaceuticals is trading at a lower price-to-earnings ratio than Knight Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Knight Therapeutics	C$510.45M	1.58	-C$30.73M	C$0.06	136.67
Cipher Pharmaceuticals	C$50.94M	8.33	C$11.41M	C$1.19	14.04

Summary

Knight Therapeutics and Cipher Pharmaceuticals tied by winning 7 of the 14 factors compared between the two stocks.

Get Cipher Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CPH vs. The Competition

Export

Metric	Cipher Pharmaceuticals	Drug Manufacturers Industry	Medical Sector	TSE Exchange
Market Cap	C$427.59M	C$2.40B	C$6.32B	C$12.18B
Dividend Yield	N/A	2.95%	2.69%	6.21%
P/E Ratio	14.04	5.19	21.04	37.99
Price / Sales	8.33	1,776.95	559.52	11.74
Price / Cash	3.53	10.18	42.31	82.29
Price / Book	3.18	10.90	9.93	4.65
Net Income	C$11.41M	C$20.70B	C$3.56B	C$299.09M
7 Day Performance	0.84%	-0.03%	-0.44%	1.44%
1 Month Performance	-6.44%	4.34%	4.59%	2.37%
1 Year Performance	35.08%	16.93%	27.59%	53.27%

Cipher Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CPH Cipher Pharmaceuticals	N/A	C$16.71 -0.8%	C$17.00 +1.7%	+34.5%	C$427.59M	C$50.94M	14.04	5	Gap Up
CRON Cronos Group	2.0275 of 5 stars	C$3.91 +4.3%	C$4.75 +21.5%	+43.9%	C$1.46B	C$159.54M	N/A	450
THCX Hydropothecary	N/A	C$5.30 +6.6%	N/A	+0.0%	C$949.11M	N/A	N/A	N/A	High Trading Volume
TLRY Tilray Brands	1.6973 of 5 stars	C$7.77 +1.4%	C$13.30 +71.2%	+35.3%	C$929.32M	C$858.28M	N/A	2,650
DHT.UN DRI Healthcare Trust	1.8757 of 5 stars	C$16.80 -0.8%	C$25.50 +51.8%	+43.2%	C$924.27M	C$163.77M	N/A	N/A

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (TSE:CPH) was last updated on 6/3/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cipher Pharmaceuticals (CPH) Competitors

CPH vs. CRON, THCX, TLRY, DHT.UN, and GUD

How does Cipher Pharmaceuticals compare to Cronos Group?

Summary

How does Cipher Pharmaceuticals compare to Hydropothecary?

Summary

How does Cipher Pharmaceuticals compare to Tilray Brands?

Summary

How does Cipher Pharmaceuticals compare to DRI Healthcare Trust?

Summary

How does Cipher Pharmaceuticals compare to Knight Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CPH vs. The Competition

Cipher Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cipher Pharmaceuticals (CPH) Competitors

CPH vs. CRON, THCX, TLRY, DHT.UN, and GUD

How does Cipher Pharmaceuticals compare to Cronos Group?

Which has preferable valuation & earnings, CPH or CRON?

Is CPH or CRON more profitable?

Does the media favor CPH or CRON?

Which has more risk & volatility, CPH or CRON?

Do analysts rate CPH or CRON?

Do insiders and institutionals have more ownership in CPH or CRON?

Summary

How does Cipher Pharmaceuticals compare to Hydropothecary?

Is CPH or THCX more profitable?

Do analysts prefer CPH or THCX?

Do institutionals and insiders believe in CPH or THCX?

Which has preferable valuation & earnings, CPH or THCX?

Does the media favor CPH or THCX?

Summary

How does Cipher Pharmaceuticals compare to Tilray Brands?

Which has preferable valuation & earnings, CPH or TLRY?

Does the media prefer CPH or TLRY?

Which has more risk & volatility, CPH or TLRY?

Do analysts recommend CPH or TLRY?

Do insiders and institutionals believe in CPH or TLRY?

Is CPH or TLRY more profitable?

Summary

How does Cipher Pharmaceuticals compare to DRI Healthcare Trust?

Do analysts rate CPH or DHT.UN?

Which has more volatility & risk, CPH or DHT.UN?

Which has better valuation and earnings, CPH or DHT.UN?

Is CPH or DHT.UN more profitable?

Does the media prefer CPH or DHT.UN?

Do insiders and institutionals have more ownership in CPH or DHT.UN?

Summary

How does Cipher Pharmaceuticals compare to Knight Therapeutics?

Does the media favor GUD or CPH?

Is GUD or CPH more profitable?

Which has more risk and volatility, GUD or CPH?

Do analysts recommend GUD or CPH?

Do insiders & institutionals have more ownership in GUD or CPH?

Which has better valuation & earnings, GUD or CPH?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CPH vs. The Competition

Cipher Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools